BL
DMK

Balentine LLC’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Balentine LLC’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-43
Closed -$13K – 550
2017
Q4 		$13K Buy
43
+29
+207% +$9.54K ﹤0.01% 443
2017
Q3 		$5K Buy
+14
New +$4.97K ﹤0.01% 525

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balentine LLC's DMK Position: Q1 2018 in Review

Balentine LLC sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2018, closing a stake of 43 shares — an estimated $13K sold.

Balentine LLC first reported a position in DMK in Q3 2017 and held it in 2 quarters. The position peaked at $13K in Q4 2017. 52 funds tracked by Wall St. Rank hold DMK as of Q1 2018.

  • Balentine LLC reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2018 after selling out during the quarter.
  • Balentine LLC sold 43 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2018, an estimated $13K.
  • Balentine LLC first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2017 and held it in 2 quarters.
  • Balentine LLC's DMK Pharmaceuticals Corporation Common Stock position peaked at $13K in Q4 2017.
  • 52 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2018.

Based on Balentine LLC's 13F filing for Q1 2018, filed 16 May 2018.